Celia Milner is a third generation cancer survivor. Now that she knows about a simple blood test to check for gene mutations, Milner is hoping the cancers will stop with her.
A breast-ovarian cancer gene test is a blood test that shows whether a woman has breast cancer or ovarian cancer gene mutations, known as BRCA 1 or 2, which increases a woman's chance of having breast, ovarian or other cancers.
MRI Better Than Mammography in Diagnosing Breast Cancer at Early Stages
A new study states that magnetic resonance imaging (MRI) is substantially more accurate than mammography in diagnosing very early stages of breast cancer.
Advertisement
September is National Gynecologic Cancer Awareness Month. More than 22,000 women will be diagnosed with ovarian cancer this year and more than 15,000 will die from this deadly cancer. Ovarian cancer ranks fifth in cancer deaths among women.
"I didn't know that if you have a family history of breast cancer, a mutation could be the cause," said Milner. "Had there been greater awareness about the gene mutation, I would have asked for this test years ago and probably would have made the decision to have a full hysterectomy. A simple blood test could have saved our family a lot of pain."
![Contraceptive Pill Protects Against Ovarian Cancer for 20 Years]( "Contraceptive Pill Protects Against Ovarian Cancer for 20 Years")
contraceptive pill is not just limited to inhibiting normal fertility, for a new study has found that these pills can protect a woman against ovarian cancer
As a result of Milner's positive test result, her sisters chose to take the BRCA test. Both tested negative. Milner hopes the negative test results will alleviate fears in her family.
Every woman is born with the breast cancer gene 1 (BRCA 1) and breast cancer gene 2 (BRCA 2). For unknown reasons, these genes can mutate, putting women at increased risk for developing breast cancer compared with women who do not have these mutations, according to Dr. Tri Dinh, a gynecologic oncologist at The Methodist Hospital.
"There's also a 50-50 chance the mutated genes can be passed on to children, both girls and boys."
In Milner's case, her maternal grandmother had thyroid, breast and brain cancer. Milner's mother had breast cancer at the age of 49, which later metastasized into her ovaries and colon. Milner had breast cancer at 33. Now age 49, she's recovering from fallopian tube cancer, the rarest of all gynecologic cancers. The blood test showed Milner has the BRCA 1 gene mutation, which is associated with a 60-80 percent greater chance of having breast cancer.
Dinh says a positive blood test in someone who is already a breast cancer survivor means the patient could one day have cancer in the other breast. In patients with the BRCA mutation, he recommends removal of the ovaries after completion of child-bearing, in order to decrease the risk of development of ovarian cancer and decrease the risk of recurrence for breast cancer.
"If the patient is young, still of child-bearing age and doesn't have cancer, but tests positive for the BRCA mutation, I usually recommend increased medical surveillance through frequent mammograms and physical exams," said Dinh.
Dinh recommends patients with multiple family members who have breast or ovarian cancer should be tested for BRCA 1 and 2. Most importantly, education and awareness about gynecologic cancers and family history, as well as annual well-woman exams, are key to reducing the incidence of these diseases.
Source: Newswise
SRM/J
Contraceptive Pill Protects Against Ovarian Cancer for 20 Years
contraceptive pill is not just limited to inhibiting normal fertility, for a new study has found that these pills can protect a woman against ovarian cancer
Advertisement
As a result of Milner's positive test result, her sisters chose to take the BRCA test. Both tested negative. Milner hopes the negative test results will alleviate fears in her family.
Every woman is born with the breast cancer gene 1 (BRCA 1) and breast cancer gene 2 (BRCA 2). For unknown reasons, these genes can mutate, putting women at increased risk for developing breast cancer compared with women who do not have these mutations, according to Dr. Tri Dinh, a gynecologic oncologist at The Methodist Hospital.
"There's also a 50-50 chance the mutated genes can be passed on to children, both girls and boys."
In Milner's case, her maternal grandmother had thyroid, breast and brain cancer. Milner's mother had breast cancer at the age of 49, which later metastasized into her ovaries and colon. Milner had breast cancer at 33. Now age 49, she's recovering from fallopian tube cancer, the rarest of all gynecologic cancers. The blood test showed Milner has the BRCA 1 gene mutation, which is associated with a 60-80 percent greater chance of having breast cancer.
Dinh says a positive blood test in someone who is already a breast cancer survivor means the patient could one day have cancer in the other breast. In patients with the BRCA mutation, he recommends removal of the ovaries after completion of child-bearing, in order to decrease the risk of development of ovarian cancer and decrease the risk of recurrence for breast cancer.
"If the patient is young, still of child-bearing age and doesn't have cancer, but tests positive for the BRCA mutation, I usually recommend increased medical surveillance through frequent mammograms and physical exams," said Dinh.
Dinh recommends patients with multiple family members who have breast or ovarian cancer should be tested for BRCA 1 and 2. Most importantly, education and awareness about gynecologic cancers and family history, as well as annual well-woman exams, are key to reducing the incidence of these diseases.
Source: Newswise
SRM/J
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Cancer News
The combination of the personalized cancer vaccine with ACT led to ovarian cancer control in few patients within a span of three months, stated study results.
Uncovering key kinases in tumor growth and invasion is crucial for improving targeted therapies in advanced-stage colorectal cancer.
The study findings validate metal-enhanced photo-oxidation for future metal-based anticancer drugs.
Mutations in 11 genes are linked to aggressive forms of prostate cancer, which may present novel therapeutic and therapy options.
Improved oral health, as indicated by the count of natural teeth and dental appointments preceding the diagnosis, correlated with enhanced head and neck cancer survival rates.
